Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1179-1183

  Campodonico, Fabio ^a   Mattioli, Francesca ^b   Manfredi, Valeria ^b   Capponi, Giacomo ^a   Pasquini, Paolo ^a   Martelli, Antonietta ^b   Maffezzini, Massimo ^a  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Gemcitabine; Intravesical chemotherapy; Pharmacokinetics; Superficial bladder cancer

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTALGIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; DYSURIA; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; URINE RETENTION; VOMITING;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 34247126698     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Maffezzini M, Audisio R, Pavone-Macaluso M and Hall RR: Bladder cancer. Crit Rev Oncol Hematol 27: 151-153, 1998.
2. Soloway MS and Masters S: Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 46: 1158-1163, 1980.
3. Pan JS, Slocum HK, Rustum YM, Greco WR, Gaeta JF and Huben RP: Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. J Urol 142: 1589-1593, 1989.
4. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA Bouffioux C, Denis L, Newling DW and Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-477, 2006.
5. Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP and Miles BJ; International Mitomycin C Consortium: Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93: 597-604, 2001.
6. Walker MC, Masters JR, Parris CN, Hepburn PJ and English PJ: Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity. Urol Res 14: 137-140, 1986.
7. Au L, Columbus OH, Badalament RA, Wientjes MG, Young DC, Schen T, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP and Miles BJ: Optimized Intravesical mitomycin C treatment for superficial bladder cancer: long-term follow-up. J Urol 175(Suppl 4): 268-269, 2006.
8. Oosterlinck W, Lobel B, Jakse, Malmstrom P, Stokle M and Stemberg C; European Association of Urology (EAU) Working Group of Oncological Urology: Guidelines on bladder cancer. Eur Urol 41: 105-112, 2002.
9. Campodonico F, Canepa G, Capponi G, Bozzo L and Maffezzini M: Intravesical gemcitabine in recurrent bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res 25: 2381-2384, 2005.
10. Hendricksen K and Witjes JA: Intravesical gemcitabine: an update of clinical results. Curr Opin Urol 16: 361-366, 2006.
11. Maffezzini M, Campodonico F, Canepa G, Capponi G and Fontana V: Short schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low or intermediate-risk transitional cell carcinoma. Eur Urol 2006 Sep 20; doi:10.1016/j.eururo.2006.08.038
12. O'Donnell MA Evanoff D and Luo Y: Studies on gemcitabine as an intravesical agent for superficial bladder cancer. J Urol 169(Suppl 4): 131-132, 2003.
13. Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A Frea B and Tizzani A: Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46: 339-343, 2004.
14. Freeman KB, Anliker S, Hamiltom M, Osborne F, Dhahir PH, Nelson R and Allerheiligen SR: Validated assay for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 665: 171-181, 1995.
15. Shah VP, Midha KK Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE and McDowall RD: Analytical method validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 16: 249-255, 1991.
16. http://ctep.cancer.gov
17. ICH Harmonised tripartite guidelines: Validation of analytical procedures: Methodology 6 Nov. 1996. FDA Federal Register 62(90): 25634-25635, 1997.
18. Palou J, Carcas A, Segarra J, Duque B, Salvador J, Garcia-Ribas I and Villavicencio H: Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 172:485-488, 2004.
19. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM and Peters GJ: Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interaction in patients with non-small cell lung cancer. J Clin Oncol 17: 2190-2197, 1999.
20. Mattioli F, Curotto A, Manfredi V, Gosmar M, Garbero C, Ambruosi C, Carmignani G and Martelli A: Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res 25: 2493-2496, 2005.
21. Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG, Trueheart IN, Eisenberg MA Nativ O and Egorin MJ: Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 21: 697-703, 2003.
22. Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, Crucitta E, Marini L and Dal Moro F: Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to the Bacillus Calmette-Guerin therapy. Urol Int 75: 309-313, 2004.